TcMedicine

Archive for June, 2008

Cholesterol may play an important role in the progression of fatty liver to an advanced stage of disease that can lead to permanent liver damage, according to a report in the September, 2006 issue of the journal Cell Metabolism, published by Cell Press. The findings suggest that low-cholesterol

NDRI is pleased to announce the receipt of a starter grant from the Josiah Macy, Jr. Foundation to support the implementation and evaluation of a training program on the hepatitis C virus for clinical and non-clinical staff in 5 New York City outpatient drug treatment programs. NDRI

Liver cirrhosis is a severe disease that may affect pulmonary circulation. Occasionally, it can lead to high blood pressure in the lung vessels, a condition called portopulmonary hypertension, a serious condition leading to increasing breathlessness, progressive impairment in exercise

ViroPharma Incorporated(Nasdaq: VPHM) today announced the presentation of additional preclinicaldata on HCV-796, an orally dosed non-nucleoside hepatitis C virus (HCV)polymerase inhibitor being co-developed with Wyeth Pharmaceuticals, adivision of Wyeth (NYSE: WYE), at the 13th International

ViroPharma Incorporated today announced preliminary data from a Phase 1b study ofHCV-796, a unique, orally dosed hepatitis C virus (HCV) polymeraseinhibitor being co-developed with Wyeth Pharmaceuticals, a division ofWyeth (NYSE: WYE). Preliminary antiviral data are available in the doserange

Combined liver and kidney transplant appears to benefit patients with diseases in both organs, including those with a condition known as hepatorenal syndrome who have been receiving dialysis for more than two months, according to an article in the August issue of Archives of Surgery, one of the

New UCLA research shows that combined liver-kidney transplants appear to benefit patients with diseases in both organs, including patients with potentially reversible kidney failure who have been receiving dialysis for longer than two months. The Archives of Surgery will publish the findings in

ViroPharma Incorporated (Nasdaq: VPHM) and Wyeth (NYSE: WYE) todayannounced that while the analysis of data from their Phase 1b study ofHCV-796, an investigational oral non-nucleoside hepatitis C virus (HCV)polymerase inhibitor, in combination with pegylated interferon, is stillongoing, data

The mystery surrounding Hepatitis C, a disease that affects millions of people worldwide, is one step closer to being solved.

In a paper published in the August edition of Journal of Virology, scientists describe how they replicated, or reproduced the hepatitis C virus (HCV) in mouse

Abbott (NYSE: ABT)announced today it received approval from the U.S. Food and DrugAdministration for its ABBOTT PRISM(R) hepatitis B surface antigen (HBsAg)and its PRISM(R) HBsAg Confirmatory test. These tests can be used bylaboratory technicians to screen donated blood for HBsAg.